Logo

Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III PRIME2 Trial for the Treatment of Prurigo Nodularis

Share this
Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III PRIME2 Trial for the Treatment of Prurigo Nodularis

Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III PRIME2 Trial for the Treatment of Prurigo Nodularis

Shots:

  • The P-III PRIME2 trial evaluates Dupixent vs PBO with/out topical treatments in 160 adults with PN inadequately controlled with topical prescription therapies
  • The trial met its 1EPs and all key 2EPs i.e.- patients experienced a reduction in itch from baseline (37% vs 22%) @12wks.; reduction in itch from baseline (58% vs 20%) & patients achieved clear or almost clear skin (45% vs 16%) @24wks.- greater improvements in measures of health-related QoL- skin pain & symptoms of anxiety & depression
  • Additionally- safety results were consistent with the known safety profile of Dupixent in its approved indications- patients discontinued the treatment (3% & 30%) before 24wks.

Click here ­to­ read full press release/ article | Ref: PR Newswire | Image: The Print


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family